Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
22 authors.
Yulia Y TyurinaDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.
Karolina Mikulska-RuminskaInstitute of Physics, Faculty of Physics, Astronomy and Informatics, Nicolaus Copernicus University in Torun, Torun, Poland.ORCID 0000-0001-7227-5503
Vladimir A TyurinDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.
Brian A KleiboekerDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.ORCID 0000-0002-3196-1803
Alexander A KapralovDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.ORCID 0000-0002-3006-916X
Ayumi HashimotoAstraZeneca, ICC, Early Oncology R&D, Gaithersburg, MD, USA.
Louis J SparveroDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.ORCID 0000-0001-6347-8448
Haider H DarDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.ORCID 0000-0001-9586-7288
Mert AkdoganDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.
Kazuhiro YamadaDepartment of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.ORCID 0000-0001-6460-8312
Jinming ZhaoDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.ORCID 0000-0003-4700-9734
Taha KelestemurDepartment of Pediatrics, Division of Critical Care and Hospital Medicine, Children's Redox Health Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-3616-1204
Ecem SaritasDepartment of Pediatrics, Division of Critical Care and Hospital Medicine, Children's Redox Health Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Sviatlana N SamovichDepartment of Pediatrics, Division of Critical Care and Hospital Medicine, Children's Redox Health Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.
Theodore R HolmanDepartment of Chemistry and Biochemistry University of California Santa Cruz, Santa Cruz, CA, USA.ORCID 0000-0001-8072-2959
Yuri L BunimovichDepartment of Dermatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID 0000-0002-7920-8781
Yulia NefedovaThe Wistar Institute, Philadelphia, PA, USA.
Dmitry I GabrilovichAstraZeneca, ICC, Early Oncology R&D, Gaithersburg, MD, USA.ORCID 0000-0001-9913-6407
Sally E WenzelDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA.ORCID 0000-0002-4242-0164
Ivet BaharLaufer Center for Physical and Quantitative Biology, Stony Brook University, New York, NY, USA.ORCID 0000-0001-9959-4176
Valerian E KaganDepartment of Environmental and Occupational Health, School of Public Health, Pittsburgh, PA, USA. kagan@pitt.edu.ORCID 0000-0002-7245-1885
Hülya BayırDepartment of Pediatrics, Division of Critical Care and Hospital Medicine, Children's Redox Health Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA. hb2753@cumc.columbia.edu.ORCID 0000-0003-2361-4120
Funding
Toward a Deeper Understanding of Allostery and Allotargeting by Computational ApproachesR01GM139297 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Ivet Bahar · 2021 to 2026
$2.8M
NIGMS NIH HHS R01 GM139297U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA243142U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA272946U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) HL174611U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI145406U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI156923U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI156924U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM139297U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS) NS076511
6 · The paper itself
Abstract
Ether (alkyl/alkenyl) phospholipids, particularly phosphatidylethanolamine (PE) and phosphatidylcholine (PC), are broadly represented in membranes, but their physiological functions are poorly characterized. The antioxidant role of plasmalogens realized via oxidation of sn-1 vinyl bond has been associated with anti-ferroptotic regulatory function. Alternatively, peroxidation of polyunsaturated fatty acid (PUFA) in sn-2-position of alkenyl-PEs can be pro-ferroptotic. Since 15-LOXs generate 15-HpETE-PEs as ferroptotic signals, we explored alkyl/alkenyl-ETE-PE as substrates of enzymatic peroxidation. Using redox lipidomics, biochemical, biophysical, genetic approaches, and molecular dynamics simulations, we established that both isoforms of 15-LOX (15-LOX-1 and 15-LOX-2) selectively oxidize alkyl/alkenyl-ETE-PE (but not alkyl/alkenyl-ETE-PC), forming 15-HpETE-PEs, triggering ferroptotic death, independently of the vinyl bond. We showed that LOX-catalyzed peroxidation rate of sn-1 vinyl bond is ~500-fold lower than sn-2-ETE-PE, thus excluding the antioxidant role of plasmalogens in ferroptosis. We showed 15-LOX-driven production of sn-1-alkenyl-sn-2-15-HpETE-PE acts as pathogenic factor in acute/chronic diseases: asthma, cancer, brain trauma, skin UVB-injury. Thus, 15-LOX-catalyzed bias towards oxidation of alkenyl-ETE-PE may represent a new therapeutic target.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
15-LOX-catalytic bias towards ether-(alkenyl)-ETE-PEs oxidation bestows selectivity of PRO-ferroptotic cell death signaling. · full record | OpenQuestion